{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:58:06Z","timestamp":1792634286460,"version":"4.5.0"},"reference-count":161,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T00:00:00Z","timestamp":1416787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Kaposi\u2019s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi\u2019s sarcoma, primary effusion lymphoma and multicentric Castleman\u2019s disease. Since the discovery of KSHV 20 years ago, there is still no standard treatment and the management of virus-associated malignancies remains toxic and incompletely efficacious. As the majority of tumor cells are latently infected with KSHV, currently marketed antivirals that target the virus lytic cycle have shown inconsistent results in clinic. Nevertheless, lytic replication plays a major role in disease progression and virus dissemination. Case reports and retrospective studies have pointed out the benefit of antiviral therapy in the treatment and prevention of KSHV-associated diseases. As a consequence, potent and selective antivirals are needed. This review focuses on the anti-KSHV activity, mode of action and current status of antiviral drugs targeting KSHV lytic cycle. Among these drugs, different subclasses of viral DNA polymerase inhibitors and compounds that do not target the viral DNA polymerase are being discussed. We also cover molecules that target cellular kinases, as well as the potential of new drug targets and animal models for antiviral testing.<\/jats:p>","DOI":"10.3390\/v6114731","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T11:06:32Z","timestamp":1416827192000},"page":"4731-4759","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication"],"prefix":"10.3390","volume":"6","author":[{"given":"Natacha","family":"Coen","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Duraffour","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2014,11,24]]},"reference":[{"key":"ref_1","first-page":"181","article-title":"Kaposi\u2019s sarcoma associated with AIDS","volume":"4","author":"Stanescu","year":"2007","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/CMR.15.3.439-464.2002","article-title":"Spectrum of Kaposi\u2019s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases","volume":"15","author":"Ablashi","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1128\/MMBR.67.2.175-212.2003","article-title":"Molecular genetics of Kaposi\u2019s sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis","volume":"67","author":"Dourmishev","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.meegid.2009.10.009","article-title":"Genetic diversity and molecular evolution of human and non-human primate Gammaherpesvirinae","volume":"10","author":"Lacoste","year":"2010","journal-title":"Infect. Genet. Evol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.humpath.2008.02.010","article-title":"Human herpesvirus 8 infections in patients with immunodeficiencies","volume":"39","author":"Laurent","year":"2008","journal-title":"Hum. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1086\/592298","article-title":"HIV\/AIDS: Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease","volume":"47","author":"Sullivan","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tripleo.2011.05.011","article-title":"Kaposi sarcoma: Review and medical management update","volume":"113","author":"Fatahzadeh","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jso.20090","article-title":"Kaposi\u2019s sarcoma: An update","volume":"87","author":"Schwartz","year":"2004","journal-title":"J. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(02)00263-3","article-title":"Update on Kaposi\u2019s sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy","volume":"2","author":"Hengge","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","first-page":"230","article-title":"Kaposi\u2019s sarcoma revisited","volume":"9","author":"Szajerka","year":"2007","journal-title":"AIDS Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"931952","DOI":"10.1155\/2012\/931952","article-title":"Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders","volume":"2012","author":"Martorelli","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0889-8588(03)00043-1","article-title":"Clinical presentations and standard therapy of AIDS-associated Kaposi\u2019s sarcoma","volume":"17","year":"2003","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ctrv.2006.06.001","article-title":"Systemic treatment of AIDS-related Kaposi sarcoma: Current status and perspectives","volume":"32","author":"Vanni","year":"2006","journal-title":"Cancer Treat. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2011.02.006","article-title":"Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma","volume":"305","author":"Uldrick","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_16","first-page":"289","article-title":"The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma","volume":"312","author":"Casper","year":"2007","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1086\/516108","article-title":"Effect of treatment with zidovudine on subsequent incidence of Kaposi\u2019s sarcoma","volume":"25","author":"Joffe","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(03)01192-6","article-title":"Use of HIV protease inhibitors to block Kaposi\u2019s sarcoma and tumour growth","volume":"4","author":"Sgadari","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jac\/49.2.359","article-title":"Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase","volume":"49","author":"Lock","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCO.0b013e328363dfee","article-title":"Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention","volume":"25","author":"Gantt","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/AAC.01295-10","article-title":"The HIV protease inhibitor nelfinavir inhibits Kaposi\u2019s sarcoma-associated herpesvirus replication in vitro","volume":"55","author":"Gantt","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clindermatol.2013.01.008","article-title":"Kaposi\u2019s sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies","volume":"31","author":"Ruocco","year":"2013","journal-title":"Clin. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","article-title":"Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study","volume":"21","author":"Simonelli","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fmicb.2012.00141","article-title":"Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers","volume":"3","author":"Dittmer","year":"2012","journal-title":"Front Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00277-005-1040-6","article-title":"Primary effusion lymphoma: Successful treatment with highly active antiretroviral therapy and rituximab","volume":"84","author":"Lim","year":"2005","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00063030-200923020-00001","article-title":"Targeted therapy for Kaposi sarcoma","volume":"23","author":"Sullivan","year":"2009","journal-title":"BioDrugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","article-title":"Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease","volume":"116","author":"Song","year":"2010","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/nm1013-1193","article-title":"First IL-6-blocking drug nears approval for rare blood disorder","volume":"19","author":"Williams","year":"2013","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood-2003-03-0951","article-title":"Rituximab therapy for HIV-associated Castleman disease","volume":"102","author":"Marcelin","year":"2003","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.20283","article-title":"Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena","volume":"78","author":"Ocio","year":"2005","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2003-05-1721","article-title":"Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.biocel.2005.01.018","article-title":"Spindle cells and their role in Kaposi\u2019s sarcoma","volume":"37","author":"Gessain","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/QCO.0b013e3283486d04","article-title":"Human herpesvirus 8-associated neoplasms: The roles of viral replication and antiviral treatment","volume":"24","author":"Gantt","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/500560","article-title":"Quantitative analysis of Kaposi sarcoma-associated herpesvirus (KSHV) in KSHV-associated diseases","volume":"193","author":"Sato","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/infdis\/173.6.1477","article-title":"Use of antiherpes drugs and the risk of Kaposi\u2019s sarcoma: Data from the Multicenter AIDS Cohort Study","volume":"173","author":"Glesby","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_36","first-page":"1101","article-title":"Anti-herpesvirus treatment and risk of Kaposi\u2019s sarcoma in HIV infection. Royal Free\/Chelsea and Westminster Hospitals Collaborative Group","volume":"10","author":"Mocroft","year":"1996","journal-title":"AIDS"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJM199606063342302","article-title":"Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group","volume":"334","author":"Spector","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/588820","article-title":"Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebo-controlled, crossover trial","volume":"198","author":"Casper","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/346159","article-title":"A pilot study of cidofovir in patients with kaposi sarcoma","volume":"187","author":"Little","year":"2003","journal-title":"J. Infect Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1097\/00002030-200110190-00026","article-title":"Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi\u2019s sarcoma progression in two patients with AIDS","volume":"15","author":"Mazzi","year":"2001","journal-title":"AIDS"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1096-9071(199807)55:3<215::AID-JMV6>3.0.CO;2-4","article-title":"Treatment of classical Kaposi\u2019s sarcoma with intralesional injections of cidofovir: Report of a case","volume":"55","author":"Simonart","year":"1998","journal-title":"J. Med. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13637","DOI":"10.1128\/JVI.78.24.13637-13652.2004","article-title":"Dissection of the Kaposi\u2019s sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir","volume":"78","author":"Lu","year":"2004","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/01.aids.0000237381.92303.61","article-title":"Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy","volume":"20","author":"Wallace","year":"2006","journal-title":"AIDS"},{"key":"ref_44","first-page":"1112","article-title":"Novel association of haemophagocytic syndrome with Kaposi\u2019s sarcoma-associated herpesvirus-related primary effusion lymphoma","volume":"111","author":"Pastore","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00002030-200101260-00023","article-title":"Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy","volume":"15","author":"Hocqueloux","year":"2001","journal-title":"AIDS"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.leu.2403646","article-title":"Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir","volume":"19","author":"Luppi","year":"2005","journal-title":"Leukemia"},{"key":"ref_47","first-page":"19","article-title":"Human herpesvirus 8 (HHV8). II. Pathogenic role and sensitivity to antiviral drugs","volume":"57","author":"Boulanger","year":"1999","journal-title":"Ann. Biol. Clin. (Paris)"},{"key":"ref_48","first-page":"372","article-title":"Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma","volume":"8","author":"Moyo","year":"2010","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1157\/13079178","article-title":"Favorable outcome of Castleman\u2019s disease treated with oral valganciclovir","volume":"125","author":"Valencia","year":"2005","journal-title":"Med. Clin. (Barc.)"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood-2004-01-0158","article-title":"Failure of cidofovir in HIV-associated multicentric Castleman disease","volume":"103","author":"Berezne","year":"2004","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","article-title":"High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: A pilot study of virus-activated cytotoxic therapy","volume":"117","author":"Uldrick","year":"2011","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Dittmer, D., and Krown, S.E. (2010). Molecular Basis for Therapy if AIDS-defining Cancers, Springer.","DOI":"10.1007\/978-1-4419-1513-9"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.cco.0000172823.01190.6c","article-title":"Targeting human herpesvirus-8 for treatment of Kaposi\u2019s sarcoma and primary effusion lymphoma","volume":"17","author":"Klass","year":"2005","journal-title":"Curr. Opin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1182\/blood-2004-09-3569","article-title":"The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production","volume":"105","author":"Klass","year":"2005","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1086\/648447","article-title":"Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid","volume":"49","author":"Lechowicz","year":"2009","journal-title":"Clin. Infec. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm.1864","article-title":"Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors","volume":"14","author":"Fu","year":"2008","journal-title":"Nature Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/CCO.0b013e3283499c37","article-title":"Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: Oncolytic strategies","volume":"23","author":"Reid","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/135965350501000609","article-title":"Prostratin and bortezomib are novel inducers of latent Kaposi\u2019s sarcoma-associated herpesvirus","volume":"10","author":"Brown","year":"2005","journal-title":"Antivir. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1172\/JCI64503","article-title":"Efficacious proteasome\/HDAC inhibitor combination therapy for primary effusion lymphoma","volume":"123","author":"Bhatt","year":"2013","journal-title":"J. Clin. Invest"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1099\/0022-1317-24-3-465","article-title":"Induction of both thymidine and deoxycytidine kinase activity by herpes viruses","volume":"24","author":"Jamieson","year":"1974","journal-title":"J. Gen. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/0006-2952(82)90305-7","article-title":"Phosphorylation of acyclovir diphosphate by cellular enzymes","volume":"31","author":"Miller","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"ref_62","unstructured":"Cameron, C.E., Gotte, M., and Raney, K. (2009). Viral Genome Replication, Springer."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/JVI.74.2.684-692.2000","article-title":"Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir","volume":"74","author":"Gustafson","year":"2000","journal-title":"J. Virol"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1128\/JVI.73.6.4786-4793.1999","article-title":"Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir","volume":"73","author":"Cannon","year":"1999","journal-title":"J. Virol"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","article-title":"Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster","volume":"68","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1128\/AAC.42.11.2923","article-title":"The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase","volume":"42","author":"Gustafson","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2005.05.001","article-title":"Antiviral drug discovery and development: Where chemistry meets with biomedicine","volume":"67","year":"2005","journal-title":"Antivir. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1016\/S0021-9258(18)83248-3","article-title":"Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate","volume":"264","author":"Reardon","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2011.08988.x","article-title":"Management of multidrug-resistant viruses in the immunocompromised host","volume":"156","author":"Sellar","year":"2012","journal-title":"Br. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/rmv.336","article-title":"Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8","volume":"11","author":"Naesens","year":"2001","journal-title":"Rev. Med. Virol"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1128\/AAC.41.12.2754","article-title":"Antiviral drug susceptibility of human herpesvirus 8","volume":"41","author":"Neyts","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2003.12.005","article-title":"Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay","volume":"62","author":"Friedrichs","year":"2004","journal-title":"Antivir. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1128\/JCM.03234-12","article-title":"Evaluation of Epstein-Barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays","volume":"51","author":"Bounaadja","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1128\/JCM.41.8.3897-3900.2003","article-title":"Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR","volume":"41","author":"Sergerie","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/00002030-199711000-00006","article-title":"In vitro antiviral drug sensitivity of the Kaposi\u2019s sarcoma-associated herpesvirus","volume":"11","author":"Medveczky","year":"1997","journal-title":"AIDS"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1128\/AAC.39.7.1599","article-title":"Activity of penciclovir against Epstein-Barr virus","volume":"39","author":"Bacon","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jac\/37.2.303","article-title":"Activity of penciclovir in antiviral assays against herpes simplex virus","volume":"37","author":"Bacon","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0166-3542(00)00144-3","article-title":"Anti-herpesvirus activity of (1\u2019S,2\u2019R)-9-[[1\u2019,2\u2019-bis(hydroxymethyl)-cycloprop-1\u2019-yl]methyl] x guanine (A-5021) in vitro and in vivo","volume":"49","author":"Neyts","year":"2001","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","article-title":"Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections","volume":"39","author":"Faulds","year":"1990","journal-title":"Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3527(08)60082-2","article-title":"Antiviral agents: Characteristic activity spectrum depending on the molecular target with which they interact","volume":"42","year":"1993","journal-title":"Adv. Virus Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.53.1.157","article-title":"Intracellular metabolism of the N7-substituted acyclic nucleoside analog 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a potent inhibitor of herpesvirus replication","volume":"53","author":"Neyts","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(97)00034-X","article-title":"Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: A quantitative analysis using recombinant vaccinia viruses","volume":"36","author":"Zimmermann","year":"1997","journal-title":"Antiviral Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.38.12.2710","article-title":"The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication","volume":"38","author":"Neyts","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187152609787847758","article-title":"Drug targets in cytomegalovirus infection","volume":"9","author":"Andrei","year":"2009","journal-title":"Infec. Dis. Drug Targets"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1128\/AAC.00468-10","article-title":"Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir","volume":"54","author":"Gentry","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.bmc.2012.02.031","article-title":"Synthesis and antiviral activity of 6-deoxycyclopropavir, a new prodrug of cyclopropavir","volume":"20","author":"Li","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1128\/AAC.00429-13","article-title":"Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses","volume":"57","author":"Prichard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1128\/JVI.03338-12","article-title":"Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses","volume":"87","author":"Coen","year":"2013","journal-title":"J. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1128\/AAC.32.7.1068","article-title":"Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2\u2019-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication","volume":"32","author":"Lin","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/jm990543n","article-title":"Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses","volume":"43","author":"Choi","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.42.1.170","article-title":"In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents","volume":"42","author":"Neyts","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/AAC.22.3.421","article-title":"Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2\u2019-deoxyuridine in mice","volume":"22","author":"Zhang","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/095632020001100404","article-title":"Novel mouse models for the investigation of experimental drugs with activity against human varicella-zoster virus","volume":"11","author":"Weber","year":"2000","journal-title":"Antiviral Chem. Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1128\/AAC.49.12.4965-4973.2005","article-title":"Potent antiviral activity of north-methanocarbathymidine against Kaposi\u2019s sarcoma-associated herpesvirus","volume":"49","author":"Zhu","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1128\/AAC.02825-14","article-title":"Anti-herpesvirus Activity of Two Novel 4\u2019-Thiothymidine Derivatives KAY-2-41 and KAH-39-149 is dependent on viral and cellular thymidine kinases","volume":"58","author":"Coen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"12422","DOI":"10.1128\/JVI.02231-13","article-title":"Evaluation of Novel Acyclic Nucleoside Phosphonates against Human and Animal Gammaherpesviruses Revealed an Altered Metabolism of Cyclic Prodrugs upon Epstein-Barr Virus Reactivation in P3HR-1 Cells","volume":"87","author":"Coen","year":"2013","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2004.10.003","article-title":"Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity","volume":"65","author":"Hartline","year":"2005","journal-title":"Antivir. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2005.09.005","article-title":"Chemical library screen for novel inhibitors of Kaposi\u2019s sarcoma-associated herpesvirus processive DNA synthesis","volume":"69","author":"Dorjsuren","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"Holy","year":"1986","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.antiviral.2006.05.020","article-title":"Perspectives on the development of acyclic nucleotide analogs as antiviral drugs","volume":"71","author":"Lee","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs\u2014The development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"Field","year":"2006","journal-title":"Br. J. Pharmacol"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: A key class of antiviral drugs","volume":"4","author":"Holy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0166-3542(91)90057-X","article-title":"Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro","volume":"16","author":"Neyts","year":"1991","journal-title":"Antivir. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0026-895X(25)08828-5","article-title":"Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine","volume":"41","author":"Ho","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"ref_108","first-page":"99","article-title":"The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond","volume":"2","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Magel, G., and Tyring, S. (2012). Herpesviridae\u2014A Look Into This Unique Family of Viruses, InTech.","DOI":"10.5772\/1207"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2174\/1381612033453668","article-title":"Phosphonomethoxyalkyl analogs of nucleotides","volume":"9","author":"Holy","year":"2003","journal-title":"Cur. Pharmac. Des."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/jm061281+","article-title":"Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds","volume":"50","author":"Krecmerova","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1016\/j.bmc.2011.04.016","article-title":"New prodrugs of Adefovir and Cidofovir","volume":"19","author":"Tichy","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/v3010047","article-title":"Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/0002-9343(92)90329-A","article-title":"Mechanism of action of foscarnet against viral polymerases","volume":"92","author":"Crumpacker","year":"1992","journal-title":"Am. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0166-0934(00)00190-7","article-title":"A rapid plate assay for the screening of inhibitors against herpesvirus DNA polymerases and processivity factors","volume":"88","author":"Lin","year":"2000","journal-title":"J. Virol. Methods"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.01259-13","article-title":"Antiviral activity of (+)-rutamarin against Kaposi\u2019s sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II","volume":"58","author":"Xu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2013.07.009","article-title":"Antiviral activity of angelicin against gammaherpesviruses","volume":"100","author":"Cho","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e33364","DOI":"10.1371\/journal.pone.0033364","article-title":"Resveratrol inhibits KSHV reactivation by lowering the levels of cellular EGR-1","volume":"7","author":"Dyson","year":"2012","journal-title":"PLoS One"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1741-7015-2-34","article-title":"Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro","volume":"2","author":"Medveczky","year":"2004","journal-title":"BMC. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.vetmic.2006.06.006","article-title":"Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers","volume":"117","author":"Zhang","year":"2006","journal-title":"Vet. Microbiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1517\/13543776.2014.927442","article-title":"Anti-herpesvirus agents: A patent and literature review (2003 to present)","volume":"24","author":"Skorenski","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1021\/jm030810w","article-title":"Design and synthesis of pyrrolidine-5,5\u2019-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability","volume":"46","author":"Borthwick","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/jm030540h","article-title":"Design and syntheses of 1,6-naphthalene derivatives as selective HCMV protease inhibitors","volume":"47","author":"Gopalsamy","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/med.20030","article-title":"Design of translactam HCMV protease inhibitors as potent antivirals","volume":"25","author":"Borthwick","year":"2005","journal-title":"Med. Res. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nchembio.192","article-title":"Inhibition of a viral enzyme by a small-molecule dimer disruptor","volume":"5","author":"Shahian","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jmb.2011.06.032","article-title":"Enzyme inhibition by allosteric capture of an inactive conformation","volume":"411","author":"Lee","year":"2011","journal-title":"J Mol. Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/bi5003234","article-title":"Broad-spectrum allosteric inhibition of herpesvirus proteases","volume":"53","author":"Gable","year":"2014","journal-title":"Biochemistry"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4614-5037-5_7","article-title":"The helicase-primase complex as a target for effective herpesvirus antivirals","volume":"767","author":"Field","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.48.5.1647-1651.2004","article-title":"Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus","volume":"48","author":"Underwood","year":"2004","journal-title":"Antimicrobial. Agents Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/48.6.757","article-title":"Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38\u20134766): In vitro and in vivo antiviral activity and mechanism of action","volume":"48","author":"Reefschlaeger","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tim.2013.03.005","article-title":"Potential of protein kinase inhibitors for treating herpesvirus-associated disease","volume":"21","author":"Li","year":"2013","journal-title":"Trends Microbiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-12-405880-4.00004-4","article-title":"Advances in the treatment of varicella-zoster virus infections","volume":"67","author":"Andrei","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e14535","DOI":"10.1371\/journal.pone.0014535","article-title":"Rapamycin blocks production of KSHV\/HHV8: insights into the anti-tumor activity of an immunosuppressant drug","volume":"6","author":"Nichols","year":"2011","journal-title":"PLoS One"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1098\/rstb.2000.0779","article-title":"Natural history of murine gamma-herpesvirus infection","volume":"356","author":"Nash","year":"2001","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0966-842X(98)01306-7","article-title":"Murine gammaherpesvirus 68: A model for the study of gammaherpesvirus pathogenesis","volume":"6","author":"Simas","year":"1998","journal-title":"Trends Microbiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1369-5274(99)80071-X","article-title":"Host and viral genetics of chronic infection: A mouse model of gamma-herpesvirus pathogenesis","volume":"2","author":"Speck","year":"1999","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4149\/av_2013_02_105","article-title":"Biological and pathogenetic characterization of different isolates of murine gammaherpesvirus 68 (MHV-68) in the context of study of human oncogenic gammaherpesviruses","volume":"57","author":"Chalupkova","year":"2013","journal-title":"Acta Virol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.vaccine.2003.10.015","article-title":"Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection","volume":"22","author":"Arico","year":"2004","journal-title":"Vaccine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1099\/vir.0.19592-0","article-title":"Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant","volume":"85","author":"Boname","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1099\/vir.0.19760-0","article-title":"Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73","volume":"85","author":"Fowler","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1128\/JVI.01543-09","article-title":"Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency","volume":"84","author":"Jia","year":"2010","journal-title":"J. Virol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.4049\/jimmunol.179.12.8392","article-title":"A replication-deficient murine gamma-herpesvirus blocked in late viral gene expression can establish latency and elicit protective cellular immunity","volume":"179","author":"Kayhan","year":"2007","journal-title":"J. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"10829","DOI":"10.1128\/JVI.78.19.10829-10832.2004","article-title":"T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics","volume":"78","author":"Obar","year":"2004","journal-title":"J. Virol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1128\/JVI.78.17.9215-9223.2004","article-title":"Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection","volume":"78","author":"Rickabaugh","year":"2004","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/JVI.72.2.943-949.1998","article-title":"Kinetic analysis of the specific host response to a murine gammaherpesvirus","volume":"72","author":"Stevenson","year":"1998","journal-title":"J. Virol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0264-410X(98)00190-X","article-title":"Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: A model system for gamma-herpesvirus vaccination","volume":"17","author":"Stewart","year":"1999","journal-title":"Vaccine"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/JVI.77.4.2522-2529.2003","article-title":"Effective vaccination against long-term gammaherpesvirus latency","volume":"77","author":"Tibbetts","year":"2003","journal-title":"J. Virol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.1128\/JVI.75.17.8283-8288.2001","article-title":"Latent antigen vaccination in a model gammaherpesvirus infection","volume":"75","author":"Usherwood","year":"2001","journal-title":"J. Virol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/088282401753266747","article-title":"Vaccination against murine gamma-herpesvirus infection","volume":"14","author":"Woodland","year":"2001","journal-title":"Viral Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.coviro.2012.06.005","article-title":"Vaccine prospect of Kaposi sarcoma-associated herpesvirus","volume":"2","author":"Wu","year":"2012","journal-title":"Cur. Opin. Virol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12026-010-8172-z","article-title":"Prospects of a novel vaccination strategy for human gamma-herpesviruses","volume":"48","author":"Wu","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/095632029901000603","article-title":"2\u2019-Deoxy-5-ethyl-beta-4\u2019-thiouridine inhibits replication of murine gammaherpesvirus and delays the onset of virus latency","volume":"10","author":"Barnes","year":"1999","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1172\/JCI27249","article-title":"KSHV targets multiple leukocyte lineages during long-term productive infection in NOD\/SCID mice","volume":"116","author":"Parsons","year":"2006","journal-title":"J. Clin. Invest."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2005-04-1697","article-title":"KSHV\/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: Persistence of infection during hematopoiesis in vitro and in vivo","volume":"108","author":"Wu","year":"2006","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.4161\/cbt.8.22.9743","article-title":"Inhibition of KSHV-infected primary effusion lymphomas in NOD\/SCID mice by gamma-secretase inhibitor","volume":"8","author":"Lan","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3390\/md11093410","article-title":"Hippuristanol reduces the viability of primary effusion lymphoma cells both in vitro and in vivo","volume":"11","author":"Ishikawa","year":"2013","journal-title":"Mar. Drugs"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2013.08.045","article-title":"HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-kappaB pathway","volume":"342","author":"Kariya","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.leukres.2004.11.010","article-title":"Inhibition of HHV-8\/KSHV infected primary effusion lymphomas in NOD\/SCID mice by azidothymidine and interferon-alpha","volume":"29","author":"Wu","year":"2005","journal-title":"Leukemia Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e90349","DOI":"10.1371\/journal.pone.0090349","article-title":"Systematic analysis of a xenograft mice model for KSHV+ primary effusion lymphoma (PEL)","volume":"9","author":"Dai","year":"2014","journal-title":"PLoS One"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/6\/11\/4731\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:09:50Z","timestamp":1760216990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/6\/11\/4731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,24]]},"references-count":161,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11]]}},"alternative-id":["v6114731"],"URL":"https:\/\/doi.org\/10.3390\/v6114731","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,24]]}}}